Physician profile
Mina Bhatnagar
NPI 1861029910
$2,618.87
in general payments reported to CMS, 2019-2025
14 companies · $1,681 in 2025
The $1,681 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.83 · 2023: $235 · 2024: $691 · 2025: $1,681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,507 · Travel and Lodging: $679 · Education: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,507.42 |
| Travel and Lodging | $678.96 |
| Education | $420.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,179.94 | 2024-2025 | General - Therapies, General - Atherectomy |
| Abbott Laboratories | $700.47 | 2024-2025 | Ensite, Xience Skypoint, Amplatzer Talisman |
| Medtronic, INC. | $205.94 | 2025 | Resolute Onyx, Symplicity G3 |
| Novo Nordisk INC | $132.21 | 2023 | Wegovy |
| Cardiva Medical, INC. | $94.79 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Abiomed | $93.45 | 2024-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $67.94 | 2025 | |
| Edwards Lifesciences Corporation | $29.69 | 2025 | |
| Daiichi Sankyo INC. | $25.43 | 2023 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $23.67 | 2023 | Eliquis |
| Amgen INC. | $19.61 | 2023 | Lumakras |
| Livanova USA, INC. | $17.32 | 2023 | Protekduo |
| Sobi, INC | $16.58 | 2023 | |
| Lilly USA, LLC | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mina Bhatnagar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.